Cue Biopharma, Inc. (CUE) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CUE Hot Sheet
Join SI Premium – FREE
Cue Biopharma, Inc. (NASDAQ: CUE) reported Q1 EPS of ($0.25), $0.04 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $733.33 thousand.
For earnings history and earnings-related data on Cue Biopharma, Inc. (CUE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 3c; Offers Guidance
- ADTRAN, Inc. (ADTN) Tops Q3 EPS by 5c; offers guidance
- DuPont (DD) Tops Q3 EPS by 209c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
